This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Ebola virus

Ebola glycoprotein GP1; Ebola glycoprotein GP2

Primate studies suggest combining anti-Ebola antibodies plus interferon-a (IFNA; IFN-a) could help treat Ebola virus. In cynomolgus and rhesus macaques, ZMAb-a combination of three murine antibodies that target GP1 and GP2-plus DEF201, an adenoviral vector-delivered IFN-a, protected 75%-100% of animals when given
3 days after infection. In cynomolgus macaques, DEF201 beginning 1 day postinfection plus ZMAb beginning
4 days postinfection protected 50% of animals. Next steps include ongoing safety and toxicology studies for ZMAb and clinical testing of ZMAb and DEF201 by Defyrus Inc.

SciBX 6(45); doi:10.1038/scibx.2013.1293
Published online Nov. 21, 2013

MAbs for Ebola and use of interferon to treat infections patented; ZMAb licensed exclusively to Defyrus; DEF201 available for licensing for filovirus indications

Qiu, X. et al. Sci. Transl. Med.; published online Oct. 16, 2013;
doi:10.1126/scitranslmed.3006605
Contact: Gary P. Kobinger, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
e-mail:
gary.kobinger@phac-aspc.gc.ca